New drug cocktail targets deadly brain cancer spread in early trial
NCT ID NCT06462222
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This study tests a combination of two drugs (an immune checkpoint inhibitor and pemetrexed) given directly into the spinal fluid for people with cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). The goal is to find the safest dose and see if it helps control the disease. The trial involves 45 adults with solid tumors and positive spinal fluid tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Chest Hospital, Capital Medical University
Beijing, 101100, China
-
Cancer Center, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine
Beijing, China
-
Huizhou First Hospital Affiliated to Guangdong Medical University
Huizhou, Guangdong, China
-
The Affiliated Huizhou Hospital, Guangzhou Medical University
Huizhou, Guangdong, 516000, China
Conditions
Explore the condition pages connected to this study.